Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-25-003719
Filing Date
2025-05-15
Accepted
2025-05-15 16:34:57
Documents
48
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q phio_i10q-033125.htm   iXBRL 10-Q 520822
2 CERTIFICATION phio_ex3101.htm EX-31.1 11895
3 CERTIFICATION phio_ex3102.htm EX-31.2 12113
4 CERTIFICATION phio_ex3201.htm EX-32.1 5813
  Complete submission text file 0001683168-25-003719.txt   3089549

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE phio-20250331.xsd EX-101.SCH 23702
6 XBRL CALCULATION FILE phio-20250331_cal.xml EX-101.CAL 29408
7 XBRL DEFINITION FILE phio-20250331_def.xml EX-101.DEF 119233
8 XBRL LABEL FILE phio-20250331_lab.xml EX-101.LAB 224079
9 XBRL PRESENTATION FILE phio-20250331_pre.xml EX-101.PRE 184556
50 EXTRACTED XBRL INSTANCE DOCUMENT phio_i10q-033125_htm.xml XML 336454
Mailing Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752
Business Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752 (508) 767-3861
Phio Pharmaceuticals Corp. (Filer) CIK: 0001533040 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36304 | Film No.: 25954321
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)